SignalPoint Asset Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,339 shares of the company’s stock after acquiring an additional 930 shares during the period. SignalPoint Asset Management LLC’s holdings in Johnson & Johnson were worth $1,454,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of JNJ. Foundations Investment Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $215,000. Triangle Securities Wealth Management raised its stake in Johnson & Johnson by 0.5% during the first quarter. Triangle Securities Wealth Management now owns 23,171 shares of the company’s stock worth $3,038,000 after acquiring an additional 112 shares in the last quarter. American National Bank lifted its holdings in shares of Johnson & Johnson by 32.7% during the first quarter. American National Bank now owns 42,661 shares of the company’s stock valued at $5,594,000 after acquiring an additional 10,508 shares during the period. Red Spruce Capital LLC boosted its stake in shares of Johnson & Johnson by 1.0% in the 1st quarter. Red Spruce Capital LLC now owns 10,704 shares of the company’s stock valued at $1,404,000 after purchasing an additional 110 shares in the last quarter. Finally, Callahan Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.8% in the 1st quarter. Callahan Advisors LLC now owns 113,550 shares of the company’s stock worth $14,890,000 after purchasing an additional 882 shares during the last quarter. 68.44% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.27% of the stock is owned by company insiders.
JNJ stock opened at $145.76 on Friday. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The company has a quick ratio of 1.05, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. The company has a market cap of $383.76 billion, a P/E ratio of 21.31, a price-to-earnings-growth ratio of 3.23 and a beta of 0.69. The business’s fifty day moving average is $144.04 and its 200-day moving average is $144.14.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Thursday, July 16th. The company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The business had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. During the same quarter in the prior year, the company posted $2.58 earnings per share. The firm’s revenue was down 10.8% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a $1.01 dividend. The ex-dividend date is Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.77%. Johnson & Johnson’s dividend payout ratio is 46.54%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.